CompletedEUCTR 2011-005200-15
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder.
This historical record does not confirm current site availability.
Historical research recordMultiple countriesDepression
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
- Listed locations
- Finland · Germany and 2 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 326
- Sponsor
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Finland, Germany, Norway, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2011-005200-15
- Official title
Show the full official title
A Phase IIa, Multicenter, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-6096 for Treatment Augmentation in Patients with Major Depressive Disorder.
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Finland · Germany · Norway
1 more locations
- Sweden
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Who was this study for?
This study was for people with depression. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Esketamine Added to Standard Care for Depression With Imminent Suicide Risk
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression